immunotherapy development

ADvantage Therapeutics is a clinical-stage biotechnology company developing novel therapeutics to treat neurodegenerative conditions, with a major focus on Alzheimer's Disease. Its lead candidate AD04 is an immuno-stimulant being developed as a disease-modifying therapy for early Alzheimer's Disease. The company was founded in 2021 and has a research team and laboratory at the Vienna BioCenter.

clinical trialsmRNA therapeuticsneuroscience research

ImmunityBio is a biotechnology company founded in 2014 that develops immunotherapies and cell therapies designed to activate both innate and adaptive immune responses to treat cancer and infectious diseases. Its lead product, ANKTIVA (nogapendekin alfa inbakicept), is FDA-approved for BCG-unresponsive non-muscle invasive bladder cancer. The company also develops a natural killer cell platform and potential cancer vaccines.

cell therapyclinical trialsnatural killer cell platformresearch and manufacturing

Auni Therapeutics is a biotech company developing a next-generation immunotherapy for food allergies, with a platform designed to expand across multiple allergens and deliver durable clinical benefits. The company is led by a multidisciplinary executive team of physician-scientists, serial entrepreneurs, and operational leaders focused on translating next-generation immunology into therapeutic assets.

clinical strategydrug discovery and developmenttranslational research

Bioarchitech is a company developing multifunctional immunotherapies targeting cancer and virus-related diseases. It mines the genetic code of viruses to produce therapies that both kill cancer cells and induce immunity. Its pipeline includes BA-V151, an intravenous viral therapy based on a modified Vaccinia virus for metastatic cancer, and BA-R166, an intratumoural self-amplifying RNA immunotherapy for early-stage cancers.

RNA-based therapeuticsviral therapy development

ChemMedImmune Inc. is a biopharmaceutical company whose mission is to develop immunotherapeutic agents for the treatment of human cancer. Its pipeline includes OPN monoclonal antibodies for colorectal and pancreatic cancer immunotherapy and IFNA2-LNP01, a cationic lipid nanoparticle-encapsulated IFNα2-encoding mini-plasmid DNA for treatment of patients with lung metastases.

lipid nanoparticle drug developmentmonoclonal antibody development

Diadem Biotherapeutics engineers first-in-class extracellular vesicles to treat cancer, autoimmune and neuroimmune conditions. Its DECOSTAR™ platform addresses biophysical challenges in agonist signaling, enabling access to validated immunotherapy targets through decorated extracellular vesicles for costimulatory activation or repression.

bioengineeringextracellular vesicle engineering

DoriNano is a biotechnology company focused on nanomedicine, developing DNA origami nanoparticle technologies for drug delivery. Its DNA origami nanoparticles enable precise placement of cargo to deliver drug combinations with nanoscale precision, and preclinical efficacy has been demonstrated in multiple mouse models. The team aims to develop immunotherapies by harnessing DNA origami nanotechnology, using DNA as building material to form 3D delivery vehicles.

DNA origami nanotechnologynanoparticle drug delivery

EVOQ Therapeutics develops innovative immunotherapies to restore immune tolerance and treat autoimmune diseases. Its proprietary NanoDisc technology delivers disease-specific antigens directly to dendritic cells in the lymph nodes, liver and spleen following subcutaneous administration, targeting the root cause of autoimmune disease. The approach has been proven in preclinical models for diseases like Type 1 Diabetes, Multiple Sclerosis, and Lupus, and EVOQ has eight programs moving toward the clinical stage through independent and partnered development.

NanoDisc technologypreclinical developmentsubcutaneous administration

FireGate Biotech Inc. is a Washington, DC–based biotechnology company incorporated in Delaware. It develops multi-target immunotherapies for virology, oncology, and neuro-immunology, guided by a mechanism-led development strategy and a scientific platform with research programs and a pipeline.

mechanism-led development strategyresearch programs

Immune Foundry Labs (IFL) develops biomaterial-based platforms that precisely direct immune responses, aiming to enable better vaccines, durable tolerance, and cancer therapies. Founded at the intersection of engineering and immunology, the company works on immunotherapies including vaccines, therapies for harmful inflammation, and cancer treatments, addressing autoimmune disease, chronic inflammation, inadequate vaccine responses, and cancers that evade the immune system.

biomaterials engineeringimmunology research

INmune Bio Inc. is a clinical stage biotechnology company focused on restoring function in the innate immune system to fight disease. Its pipeline consists of first in class therapies designed to maximize benefit without compromising safety, being developed for neurologic disease and certain forms of cancer. Drug candidates INKmune and INB03 may be used to treat cancer, while XPro1595 targets neuroinflammation as a cause of Alzheimer's disease.

clinical stage drug developmentclinical trials